Enable Injections is a leading developer and manufacturer of high-volume/viscosity body-worn injectors. The late-stage startup has developed a disposable body-worn bolus injector to deliver payloads up to 20cc to the subcutaneous tissue, meetiScreen Shot 2014-11-21 at 10.44.03 AMng a substantial market potential expected to be $8B by 2024.
In October, Enable Injections signed a strategic agreement with CSL Behring for the exclusive use of one of its products on a worldwide basis with the aim of improving the comfort, convenience, and treatment compliance for patients with rare and serious diseases. President and CEO Mike Hooven explained that the Company continues to seek long-term development and manufacturing agreements that will leverage strategic partnerships with big pharma companies as a central part of its business model.
Enable expects that there will be over 250 biologic candidates for the device within the next 10 years. The device has several unique features, one of the most important being the ability to use product immediately after transfer from a refrigerator. While the technology is pre-FDA, Enable maintains an existing relationship with the organization and expects to be the first company in the country to complete clinicals and receive FDA approval with this type of technology.
Enable is not currently seeking capital, as it was oversubscribed in its Series B Round this October. The Company continues to focus much of its efforts on generating strategic partnerships, with interest in domestic and international expansion. Enable anticipates entering another 2-3 major agreements within the next few months.
Enable Injections will be presenting at the 8th Annual OneMedForum in January 2015.